Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid Xyrem Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PMN.42

    Clinical Policy: Sodium Oxybate (Xyrem)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.42 alerts

    Get alerted when Policy AZ.CP.PMN.42 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage of Xyrem for Arizona Medicaid members with narcolepsy-related cataplexy or excessive daytime sleepiness. It establishes diagnostic, specialist, age, step-therapy, dose, documentation, and continuation requirements.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Sodium Oxybate (Xyrem)
    Policy CodePolicy AZ.CP.PMN.42
    Change TypeModified
    Effective DateSep 1, 2020
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionFor members age 17 or older with narcolepsy and excessive daytime sleepiness, document a one-month trial and failure of armodafinil or modafinil before requesting sodium oxybate coverage.
    SourceLink
    POLICY UPDATE CHANGES

    A one-month trial and failure of armodafinil or modafinil is now required for members age 17 or older with narcolepsy and excessive daytime sleepiness.

    Care1st logo content and clarifying wording were added.

    Age 7+Minimum age for initial approval
    9 g/dayMaximum sodium oxybate dose
    6 monthsInitial approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsContinuation approval duration
    2Covered narcolepsy manifestations
    PSG + MSLTDiagnostic testing

    Coverage Criteria

    Initial therapy: narcolepsy with cataplexy

    Covered when ALL of the following are met:

    Diagnostic confirmation: Supporting PSG and MSLT documentation confirms daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months, presence of cataplexy, mean sleep latency of 8 minutes or less, and either 2 or more SOREMPs or CSF hypocretin-1 deficiency.Mean sleep latency ≤ 8 minutes; ≥ 2 SOREMPs or CSF hypocretin-1 deficiency
    Specialist and age: The medication is prescribed by or in consultation with a neurologist or sleep specialist in narcolepsy, and the member is at least 7 years old.Age ≥ 7 years
    Cataplexy pretreatment: For adults age 18 years or older, failure of one of the following antidepressants used for at least 1 month is documented: venlafaxine, fluoxetine, atomoxetine, clomipramine, or protriptyline. This requirement is excepted when the member is at least 65 years old, all listed agents are contraindicated, or clinically significant adverse effects occur.Trial duration ≥ 1 month
    Daytime-sleepiness pretreatment: Failure of one listed CNS stimulant, armodafinil, or modafinil used for at least 1 month at up to maximally indicated doses is documented, unless contraindicated or clinically significant adverse effects occur.Trial duration ≥ 1 month at up to maximally indicated doses

    Prior authorization may be required for armodafinil and modafinil.

    Dose: The requested dose does not exceed 9 grams (18 mL) per day.≤ 9 grams (18 mL) per day

    Initial therapy: narcolepsy with excessive daytime sleepiness

    Covered when ALL of the following are met:

    Diagnostic confirmation: Supporting PSG and MSLT documentation confirms daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months, absence of cataplexy, mean sleep latency of 8 minutes or less, at least 2 SOREMPs, and that excessive daytime sleepiness or MSLT findings are not better explained by insufficient sleep, obstructive sleep apnea, delayed sleep phase disorder, medication or substance effects, or withdrawal.Mean sleep latency ≤ 8 minutes; ≥ 2 SOREMPs
    Specialist and age: The medication is prescribed by or in consultation with a neurologist or sleep specialist in narcolepsy, and the member is at least 7 years old.Age ≥ 7 years
    CNS stimulant trial: Failure of a 1-month trial of one listed CNS stimulant at up to maximally indicated doses is documented, unless contraindicated or clinically significant adverse effects occur.Trial duration: 1 month

    Continuation therapy: covered indications

    Covered when ALL of the following are met:

    Continuation therapy for covered indications

    • Current treatment eligibility: The member is currently receiving the medication through the Centene benefit or previously met initial approval criteria.
    • Positive response: Documentation supports a positive response to therapy, including improvement such as reduced frequency of cataplexy attacks or improved daytime wakefulness.
    • Dose limit for increase requests: If the request is for a dose increase, the new dose does not exceed 9 grams (18 mL) per day.≤ 9 grams (18 mL) per day

    Continuation therapy: other diagnoses

    Covered when ONE of the following is met:

    Continuation for other diagnoses or indications

    • Existing therapy with response: The member is currently receiving the medication through the Centene benefit and documentation supports a positive response to therapy.

      Approval is limited to the duration of the request or 12 months, whichever is less.

    • Off-label policy referral: Refer to the applicable off-label use policy when the diagnosis is not specifically listed under the policy's nonauthorized indications section.

      For Arizona Medicaid, the applicable policy is AZ.CP.PMN.53.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless sufficient documentation supports the treatment’s efficacy and safety under the applicable off-label use policy for Arizona Medicaid or the member’s evidence of coverage documents.

    Clinical and Dose Parameters

    Mean sleep latency
    ThresholdMean sleep latency of 8 minutes or less
    TestMultiple Sleep Latency Test (MSLT)
    Diagnostic useReferenced as a diagnostic criterion for narcolepsy evaluation
    Narcolepsy diagnostic duration
    Required durationAt least 3 months
    Sleep symptomDaily periods of irrepressible need to sleep
    Alternative symptomDaytime lapses into sleep

    Provider Requirements and Coverage Risks

    Prior Authorization

    Clinical Prior Authorization Required

    Prior authorization is required. Submit documentation demonstrating that the member meets all applicable Xyrem approval criteria before authorization can be issued.

    • Criteria apply to the requested indication, including diagnosis, specialist involvement, age, required prior-treatment trials, and dose limits.
    Prior Authorization

    Initial Approval Duration

    Initial Xyrem therapy may be authorized for 6 months when all applicable initial approval criteria are met.

    • Applies to narcolepsy with cataplexy and narcolepsy with excessive daytime sleepiness (EDS).

    Unsupported block type: prior_auth

    Step Therapy

    Medication Background

    Sodium oxybate (Xyrem) is a central nervous system depressant indicated for members age 7 years and older with narcolepsy-related cataplexy or excessive daytime sleepiness. Because of its CNS-depressant effects, treatment should be evaluated with attention to potential CNS and respiratory depression and risks of abuse or misuse.

    Terms and Diagnostic Definitions

    CNS
    AbbreviationCNS
    Full termCentral nervous system
    Policy terminologyCNS is the abbreviation used in the policy
    CSF
    AbbreviationCSF
    Full termCerebrospinal fluid
    Policy terminologyCSF is the abbreviation used in the policy

    Initial Therapy

    Narcolepsy with cataplexy

    Initial therapy is covered when ALL applicable criteria are met:

    • Diagnostic confirmation: Daily periods of irrepressible need to sleep or daytime lapses into sleep have occurred for at least 3 months; cataplexy is present; mean sleep latency is 8 minutes or less; and there are at least 2 SOREMPs or CSF hypocretin-1 deficiency.
    • Required treatment failures or exceptions: For adults, one listed antidepressant has failed after use for at least 1 month, unless the member is at least 65 years old, all listed agents are contraindicated, or clinically significant adverse effects occur. Failure of one listed CNS stimulant, armodafinil, or modafinil used for at least 1 month at up to maximally indicated doses is also documented, unless contraindicated or clinically significant adverse effects occur.

    Narcolepsy with excessive daytime sleepiness

    Initial therapy is covered when ALL applicable criteria are met:

    Continuation Therapy

    Continuation therapy

    Continuation is covered when ALL of the following are met:

    • Current treatment eligibility: The member is currently receiving Xyrem through the Centene benefit or previously met initial approval criteria.
    • Positive response: Documentation supports a positive response to therapy, including reduced frequency of cataplexy attacks or improved daytime wakefulness.
    • Dose increase limit: If the request is for a dose increase, the new dose does not exceed 9 grams (18 mL) per day.≤ 9 grams (18 mL) per day

    Required Prior Treatment Trials

    StepPopulation or indicationRequired prior treatmentDuration and conditions
    1Adults with narcolepsy and cataplexyFailure of one listed antidepressant: venlafaxine, fluoxetine, atomoxetine, clomipramine, or protriptylineUsed for at least 1 month. Requirement does not apply if the member is age 65 or older, all listed agents are contraindicated, or clinically significant adverse effects occur.
    1Narcolepsy-related daytime sleepinessFailure of one listed CNS stimulant, armodafinil, or modafinilUsed for at least 1 month at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occur.
    StepPopulation or indicationRequired prior treatmentDuration and conditions
    2Narcolepsy with excessive daytime sleepinessFailure of a trial of one listed CNS stimulant: amphetamine immediate-release, amphetamine, dextroamphetamine immediate-release, dextroamphetamine, methylphenidate immediate-release, or Metadate ER1 month at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occur.
    2Members age 17 years or older with narcolepsy and excessive daytime sleepinessFailure of a trial of armodafinil or modafinil1 month at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occur.
    StepMember populationRequired trial before sodium oxybateRequirement
    1Members age 17 years or older with narcolepsy-related excessive daytime sleepinessArmodafinil or modafinilTrial and failure for 1 month before sodium oxybate coverage.

    Dose and Quantity Limit

    Sodium oxybate (Xyrem)
    MedicationSodium oxybate (Xyrem)
    Maximum quantity9 grams per day
    Volume equivalent18 mL per day
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Sodium Oxybate (Xyrem)
    Policy CodePolicy AZ.CP.PMN.42
    Change TypeModified
    Effective DateSep 1, 2020
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionFor members age 17 or older with narcolepsy and excessive daytime sleepiness, document a one-month trial and failure of armodafinil or modafinil before requesting sodium oxybate coverage.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Dose ParametersProvider Requirements and Coverage RisksMedication BackgroundTerms and Diagnostic DefinitionsInitial TherapyContinuation TherapyRequired Prior Treatment TrialsDose and Quantity Limit

    Listed stimulants include amphetamine immediate-release, amphetamine, dextroamphetamine immediate-release, dextroamphetamine, methylphenidate immediate-release, and Metadate ER. Prior authorization may be required.

    Additional wakefulness-agent trial for members age ≥ 17: For members age 17 years or older, failure of a 1-month trial of armodafinil or modafinil at up to maximally indicated doses is documented, unless contraindicated or clinically significant adverse effects occur.Trial duration: 1 month

    Prior authorization may be required for armodafinil and modafinil.

    Dose: The requested dose does not exceed 9 grams (18 mL) per day.≤ 9 grams (18 mL) per day
    Narcolepsy with cataplexy diagnosis
    SOREMP criterionTwo or more sleep-onset rapid eye movement periods
    Laboratory alternativeCSF hypocretin-1 deficiency
    Applicable diagnosisNarcolepsy with cataplexy; CSF hypocretin-1 deficiency is referenced for narcolepsy type 1
    Narcolepsy with EDS diagnosis
    Required SOREMPsTwo or more sleep-onset rapid eye movement periods
    Associated diagnosisNarcolepsy with excessive daytime sleepiness
    TestMultiple Sleep Latency Test (MSLT)
    Maximum Xyrem dose
    Maximum daily dose9 grams per day
    Volume equivalent18 mL per day
    Dose-increase requirementA requested dose increase must remain at or below 9 grams (18 mL) per day

    Cataplexy and Daytime-Sleepiness Pretreatment

    For narcolepsy with cataplexy, document the required pretreatment for cataplexy and daytime sleepiness. Adult members age 18 or older must have failed an applicable antidepressant trial for cataplexy, and members must have failed an applicable CNS stimulant, armodafinil, or modafinil trial for daytime sleepiness, unless an exception applies.

    • Cataplexy treatment: for members age 18 or older, document failure of at least 1 month of venlafaxine, fluoxetine, atomoxetine, clomipramine, or protriptyline.
    • The antidepressant requirement does not apply when the member is age 65 or older, all listed agents are contraindicated, or clinically significant adverse effects occurred.
    • Daytime-sleepiness treatment: document at least 1 month of an applicable agent at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred.
    Step Therapy

    EDS CNS Stimulant Step Therapy

    For narcolepsy with EDS, document failure of a 1-month trial of an applicable CNS stimulant at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred.

    • Applicable agents include amphetamine immediate-release (IR), amphetamine, dextroamphetamine IR, dextroamphetamine, methylphenidate IR, and Metadate ER.
    • Prior authorization may be required for CNS stimulants.
    Step Therapy

    Armodafinil or Modafinil Trial

    For members age 17 years or older with narcolepsy and EDS, document failure of a 1-month trial of armodafinil or modafinil at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred.

    • This armodafinil or modafinil requirement does not apply to members younger than 17 years.
    • Prior authorization may be required for armodafinil and modafinil.
    Documentation Required

    Required Supporting Documentation

    Submit supporting clinical evidence showing that the member meets all applicable approval criteria.

    • Acceptable evidence may include office chart notes, laboratory results, and other relevant clinical information.
    Documentation Required

    Diagnostic Sleep-Study Documentation

    For either narcolepsy indication, submit diagnostic sleep-study findings supporting the diagnosis.

    • Include polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results.
    • For narcolepsy with cataplexy, document mean sleep latency of 8 minutes or less and at least 2 sleep-onset REM periods (SOREMPs) or CSF hypocretin-1 deficiency.
    • For narcolepsy with EDS, document mean sleep latency of 8 minutes or less, at least 2 SOREMPs, absence of cataplexy, and that EDS or MSLT findings are not better explained by another cause.
    Documentation Required

    Prior-Treatment History

    Document the complete history of required prior treatments and the member’s response before requesting Xyrem.

    • Identify each drug, treatment duration, dose or whether it was used at up to the maximally indicated dose, and the response or reason for failure.
    • Document applicable exceptions, including contraindication or clinically significant adverse effects; for the adult cataplexy antidepressant requirement, also document age 65 or older when applicable.
    • Include relevant prior-authorization status or requirements when applicable.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, document that the member is currently receiving Xyrem through the Centene benefit or previously met initial approval criteria and is responding positively to therapy.

    • Describe improvement such as reduced frequency of cataplexy attacks or improved daytime wakefulness.
    • For other diagnoses or indications, documentation must support a positive response to therapy when relying on current treatment.
    Denial Risk

    Insufficient Clinical Documentation

    Failure to submit required clinical evidence creates a denial risk because the plan cannot confirm that applicable approval criteria are met.

    • Missing chart notes, laboratory results, PSG or MSLT findings, prior-treatment history, or continuation response documentation may result in denial or inability to authorize.
    Denial Risk

    Dose Exceeds Policy Limit

    Requests exceeding the policy dose limit create a denial risk. The requested dose must not exceed 9 grams (18 mL) per day, including a dose increase.

    • The same maximum applies to initial and continuation therapy.
    Denial Risk

    Unaddressed Non-FDA Indication

    Coverage is not authorized for non-FDA-approved indications not addressed by this policy unless sufficient efficacy and safety documentation supports use under the applicable off-label policy or evidence of coverage documents.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53 when applicable.
    Denial Risk

    Contraindication Present

    Do not use Xyrem in combination with sedative hypnotics or alcohol, or in a member with succinic semialdehyde dehydrogenase deficiency.

    • These are listed contraindications and must be assessed and documented before authorization.
    • Also evaluate boxed-warning risks, including central nervous system depression and abuse or misuse.
    EDS
    AbbreviationEDS
    Full termExcessive daytime sleepiness
    Policy terminologyEDS is the abbreviation used in the policy
    MSLT
    AbbreviationMSLT
    Full termMultiple sleep latency test
    Policy terminologyMSLT is the abbreviation used in the policy
    PSG
    AbbreviationPSG
    Full termPolysomnography
    Policy terminologyPSG is the abbreviation used in the policy
    SOREMPs
    AbbreviationSOREMPs
    Full termSleep-onset rapid eye movement periods
    Singular formSOREMP: sleep-onset rapid eye movement period
    Multiple Sleep Latency Test criteria
    Mean sleep latency8 minutes or less
    SOREMP thresholdTwo or more sleep-onset rapid eye movement periods
    AssessmentCriteria are assessed using the Multiple Sleep Latency Test
    CSF hypocretin-1 deficiency
    Narcolepsy typeNarcolepsy type 1
    Hypocretin-1 threshold110 pg/mL or less
    Alternative thresholdLess than one-third of normative values using the same standardized assay
    Sleep apnea evaluation before narcolepsy diagnosis
    PrerequisiteSleep apnea should be adequately treated before diagnosing narcolepsy
    TreatmentContinuous positive airway pressure (CPAP)
    TimingCPAP should be used for a sufficient period before making the diagnosis
  1. Diagnostic confirmation: Daily periods of irrepressible need to sleep or daytime lapses into sleep have occurred for at least 3 months; cataplexy is absent; mean sleep latency is 8 minutes or less; there are at least 2 SOREMPs; and the excessive daytime sleepiness or MSLT findings are not better explained by insufficient sleep, obstructive sleep apnea, delayed sleep phase disorder, medication or substance effects, or withdrawal.
  2. Required treatment failures or exceptions: Failure of a 1-month trial of one listed CNS stimulant at up to maximally indicated doses is documented, unless contraindicated or clinically significant adverse effects occur. For members age 17 years or older, failure of a 1-month trial of armodafinil or modafinil at up to maximally indicated doses is also documented, unless contraindicated or clinically significant adverse effects occur.